How many studies have been conducted on Sunitinib?

BiohacksAI has indexed 300 PubMed studies on Sunitinib, including 10 randomized controlled trials (RCTs). 58% of studies involve human subjects.

What are the main research areas for Sunitinib?

The primary research domains for Sunitinib are 🔬 Oncology, 🫘 Kidney, ⏳ Longevity & Aging. This is based on analysis of 300 PubMed studies using the BiohacksAI evidence platform.

BETABiohacksAI is a research tool for informational purposes only. All outputs are computational hypothesis candidates — not confirmed mechanisms, not medical advice, and not a substitute for professional medical judgment. Independent experimental validation is always required.

Sunitinib

An indole and pyrrole derivative that inhibits VEGFR-2 and PDGFR BETA RECEPTOR TYROSINE KINASES. It is used as an antineoplastic agent for the treatment of GASTROINTESTINAL STROMAL TUMORS, and for treatment of advanced or metastatic RENAL CELL CARCINOMA.

300+ PubMed studies analyzed · 10 RCTs · Evidence Score: 48.9

Research Domains

Sunitinib has been studied across 17 research domains including 🔬 Oncology, 🫘 Kidney, ⏳ Longevity & Aging, 🧬 Hormones, 🫁 Liver & Detox. The primary research focus is 🔬 Oncology with 77% of studies addressing this area.

Loading evidence profile...

This evidence profile for Sunitinib is generated deterministically from 300 PubMed-indexed studies. All data is corpus-verified with Merkle proofs. BiohacksAI does not provide medical advice. Always consult a healthcare professional before starting any supplement regimen.